Program
PF-08656795
A development code.
In Pfizer's pipeline, GLP-1 receptor agonist
. Its studies are mostly in Obesity, led by Pfizer.
Furthest: phase 1, since Oct 9, 20261 company-led study, 1 open or runningNext primary completion: Nov 16, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 11 open or running | phase 1since Oct 9, 2026 | Oct 9, 2026 | Nov 16, 2028phase 1 · NCT07876518 |
- Named in Pfizer’s own pipeline as
PF-08656795
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2026First study: phase 1 study in OverweightFirst studyNCT07876518 · 150 planned
Ahead
- Nov 16, 2028Primary completion: phase 1 study in OverweightNCT07876518
TargetBeta
“GLP-1 receptor agonist”the company's pipeline, read by Claude · source
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07876518Overweight | 1 | Not yet recruiting | Nov 16, 2028 | 150 |
How it is read
Names in the registry
- “PF-08656795”, 1 entry
Codes read as this program: PF08656795.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.